Skip to content

Gabriele Duccio Papanti

6 papers in the library · 598 citations · publishing 2015-2025

Papers

Sort Most recent Most cited

Xylazine as an emerging new psychoactive substance; focuses on both 5‐HT7 and κ‐opioid receptors' molecular interactions and isosteric replacement

Archiv der Pharmazie March 1, 2025 Giuseppe Floresta, Alberto Granzotto, Vincenzo Patamia et al. 12 citations

Abstract Xylazine, traditionally used as a veterinary sedative, has recently emerged as a new psychoactive substance, being typically ingested in combination with fentanyl derivatives and hence raising significant public health concerns. Despite its increasing prevalence, little is known about its molecular interactions with human neuroreceptors, specifically the serotonin 7 (5‐HT 7 R) and...

Comparative safety of prescribed Esketamine and ketamine in relation to renal and urinary disorders: A pharmacovigilance perspective.

Progress in neuro-psychopharmacology & biological psychiatry January 10, 2025 Stefania Chiappini, Amira Guirguis, Nicolò Schifano et al. 12 citations

Intranasal esketamine, approved with oral antidepressants for adults with treatment-resistant depression (TRD), is the S-enantiomer of ketamine and has higher potency and affinity for N-Methyl-d-Aspartate receptors. Administered intranasally, it offers rapid absorption and onset, essential for severe depressive symptoms or suicidal impulses. Comparative studies on esketamine and ketamine's...

The “Endless Trip” among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review

Frontiers in Psychiatry November 20, 2017 Laura Orsolini, Gabriele Duccio Papanti, Domenico de Berardis et al. 99 citations

Hallucinogen-persisting perception disorder (HPPD) is a syndrome characterized by prolonged or reoccurring perceptual symptoms, reminiscent of acute hallucinogen effects. HPPD was associated with a broader range of LSD (lysergic acid diethylamide)-like substances, cannabis, methylenedioxymethamphetamine (MDMA), psilocybin, mescaline, and psychostimulants. The recent emergence of novel...

Novel psychoactive substances: the pharmacology of stimulants and hallucinogens

Expert Review of Clinical Pharmacology March 17, 2016 Fabrizio Schifano, Gabriele Duccio Papanti, Laura Orsolini et al. 66 citations

There are increasing levels of concern relating to the rapidly evolving novel psychoactive substances/NPS and web markets' scenarios. The paper aims at providing an overview of the clinical pharmacological issues related to some of the most popular NPS categories, e.g. stimulants and hallucinogens. NPS intake is typically associated with the imbalance of a complex range of neurotransmitter...

Novel psychoactive substances of interest for psychiatry

World Psychiatry February 1, 2016 Fabrizio Schifano, Laura Orsolini, Gabriele Duccio Papanti et al. 319 citations

Novel psychoactive substances include synthetic cannabinoids, cathinone derivatives, psychedelic phenethylamines, novel stimulants, synthetic opioids, tryptamine derivatives, phencyclidine-like dissociatives, piperazines, GABA-A/B receptor agonists, a range of prescribedmedications, psychoactive plants/herbs, and a large series of performance and image enhancing drugs. Users are typically...

Mind navigators of chemicals' experimenters? A web-based description of e-psychonauts.

Cyberpsychology, behavior and social networking May 1, 2015 Laura Orsolini, Gabriele Duccio Papanti, Giulia Francesconi et al. 90 citations

Within online drug fora communities, there are some "educated and informed" users who can somehow provide reliable information on psychoactive compounds and combinations. These users, also called "e-psychonauts," may possess levels of technical knowledge relating to a range of novel psychoactive substances (NPS). The present project aimed at identifying and describing the e-psychonauts'...